| Biosimilar epoetin alfas have now been available in Europe for a decade. The availability of biosimilars provides an opportunity to contain spending on expensive medications while improving treatment access for patients. |
| Based on the now extensive experience with biosimilar epoetins in Europe, healthcare professionals and their patients should be reassured about the therapeutic equivalence of biosimilar epoetins. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.